Most pharmaceutical companies consider transcription factors “undruggable” even though they play critical roles in cancer, chronic kidney disease, and neurodegeneration. Using our GRETA™ platform, we can screen large compound libraries for their effect on transcriptional networks and discover drugs that target transcription factors for the first time. Our lead program selectively degrades the famous oncogenic transcription factor NRF2 in a KEAP1-mutant non-small cell lung cancer.